CC
HRTX icon

Centiva Capital’s Heron Therapeutics HRTX Stock Holding History

Centiva Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
+45,507
New +$36.5K ﹤0.01% 1711
2023
Q1 		– Sell
-30,888
Closed -$77.2K – 1656
2022
Q4 		$77.2K Buy
30,888
+16,888
+121% +$54.4K ﹤0.01% 1218
2022
Q3 		$59K Buy
+14,000
New +$54.8K ﹤0.01% 1321
2021
Q3 		– Sell
-17,296
Closed -$268K – 1430
2021
Q2 		$268K Buy
+17,296
New +$275K 0.01% 1089

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Centiva Capital's HRTX Position: Q2 2026 in Review

Centiva Capital opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 45,507 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #1711 among its holdings. This is a return to the name: Centiva Capital previously reported a position in HRTX as recently as Q4 2022.

Centiva Capital first reported a position in HRTX in Q2 2021 and has held it in 4 quarters since. The position peaked at $268K in Q2 2021. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Centiva Capital held 45,507 shares of Heron Therapeutics worth $19.4K as of Q2 2026.
  • Heron Therapeutics was a new Centiva Capital position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1711 holding.
  • Centiva Capital first reported a position in Heron Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Centiva Capital's Heron Therapeutics position peaked at $268K in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.